Status:
COMPLETED
Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases
Lead Sponsor:
University of Zurich
Conditions:
Colorectal Liver Metastases
Eligibility:
All Genders
18-90 years
Brief Summary
Hypothesis of the study: Neoadjuvant chemotherapy with Bevacizumab impairs postoperative outcome after resection of colorectal liver metastases.
Detailed Description
Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) increasingly added to other drugs in the treatment of colorectal cancer. Bev is typically used in combi...
Eligibility Criteria
Inclusion
- Patients with neoadjuvant chemotherapy prior to liver resection
Exclusion
- Patients without neoadjuvant chemotherapy
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT00875147
Start Date
April 1 2009
End Date
September 1 2009
Last Update
October 25 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Chirurgie Viscérale et de Transplantation, Hautepierre Hospital
Strasbourg, Strasbourg, France
2
Division of hepato-biliary-pancreatic surgery. Department of surgery, "Josep Tureta" Hospital
Girona, Girona, Spain
3
University Hospital of Zurich
Zurich, Canton of Zurich, Switzerland, 8091